PD98059 Influences Immune Factors and Enhances Opioid Analgesia in Model of Neuropathy

Abstract

Neuropathic pain treatment remains challenging due to ineffective therapy and resistance to opioid analgesia. Mitogen-activated protein kinase kinase (MAPKK) have been identified as the crucial regulators of pro- and antinociceptive factors. We used PD98059, an inhibitor of the MAPKK family members MEK1/2. The aim of study was to examine the influence of single and/or repeated PD98059 on nociception and opioid effectiveness in neuropathy. Moreover, we examined how PD98059 influences selected members of cellular pathways and cytokines. The PD98059 (2.5 mcg) was intrathecally preemptively administered before chronic constriction injury (CCI), and then once daily for 7 days. Additionally, at day 7 after CCI the PD98059-treated rats received a single injection of opioids. Using Western blot and qRT-PCR techniques in PD98059-treated rats we analyzed the mRNA and/or protein level of p38, ERK1/2, JNK, NF-kappaB, IL-1beta, IL-6, iNOS and IL-10 in the lumbar spinal cord. Our results indicate that PD98059 has an analgesic effects and potentiates morphine and/or buprenorphine analgesia. Parallel we observed that PD98059 inhibit upregulation of the CCI-elevated p38, ERK1/2, JNK and NF-kappaB protein levels. Moreover, PD98059 also prevented increase of pro- (IL-1beta, IL-6, and iNOS) but enhances anti-nociceptive (IL-10) factors. Summing up, PD98059 diminished pain and increased the effectiveness of opioids in neuropathy. The inhibition of MEKs might inactivate a variety of cell signaling pathways that are implicated in nociception.

About the Authors:

Ewelina Rojewska

Affiliation: Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

Katarzyna Popiolek-Barczyk

Affiliation: Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

Natalia Kolosowska

Affiliation: Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

Anna Piotrowska

Affiliation: Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

Magdalena Zychowska

Affiliation: Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

Wioletta Makuch

Affiliation: Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

Barbara Przewlocka

Affiliation: Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

Joanna Mika

* E-mail: [email protected]

Affiliation: Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland

Introduction

Treatments for neuropathic pain are not satisfactory due to our incomplete understanding of its pathogenesis. Nuclear factor-kappaB (NF-kappaB) and Mitogen-Activated Protein Kinase (MAPK)-mediated pathways have been identified as the master regulators of pro- and antinociceptive factors. Studies have highlighted the role of the MAPKs in neuropathy [1, 2]. MAPKs are a family of serine/threonine protein kinases that transduce extracellular stimuli into intracellular transcriptional and posttranslational responses [3, 4]. This family consists of three major members that play a role in neuropathy: extracellular signal-regulated kinase (ERK), p38MAPK kinase (p38), and c-Jun N-terminal kinase (JNK) [5, 6]. In 1999, Ji et al. [7] reported the nociceptive-specific activation of ERK in spinal neurons; several years later, Zhuang et al. [8] showed that ERK is sequentially activated in neurons and glia after nerve injury. It seems that ERK is essential for the intracellular signaling that leads to the production of pronociceptive mediators [8]. Nerve injury causes phosphorylation of p38 [5, 9], which can increases the synthesis of proinflammatory mediators such as interleukin-1beta (IL-1beta) [9] and inducible nitric oxide synthase (iNOS) [10]. Intrathecal administration of p38 inhibitors (SB203580, FR167653, and minocycline) can diminish nerve injury-induced hyperalgesia and allodynia [11, 12, 13, 14, 15]. Our previously study demonstrated that minocycline diminished the level of proinflammatory factors, such as IL-6, IL-18, and MMP-9, during neuropathy [16] and enhanced morphine effectiveness [17, 18, 19]. In 2011 Lee et al. [6] showed that induction of p-NF-kappaB play important roles in trigeminal neuropathy and suggested that its blockade might be beneficial. Zhuang et al. [20] investigated the role of another MAPK family member, JNK, in neuropathic pain. After spinal nerve ligation (SNL) model, they observed persistent spinal activation of JNK in astrocytes. Intrathecal injection of D-JNKI-1JNK, a peptide inhibitor of JNK, reversed SNL-induced mechanical allodynia in rats. Additionally, Gao et al. [21] have demonstrated that activation of JNK is important for the chronic pain. A lot of studies have described a crucial role of NF-kappaB in pain models [22, 23, 24, 25, 26], and it is known that NF-kappaB is responsible for cytokine production [27]. In 2014 [25] we have already shown that administration of NF-kappaB inhibitor (parthenolide) as well as MEK1/2 inhibitor (U0126) diminished pain symptoms and enhanced morphine effectiveness in a rat model of neuropathy. Recently, it has been shown that during inflammation, intrathecal injection of PD98059 (MEK1/2 inhibitor) diminished the painful response to formalin injection in rats [7] and mice [28]. Zhuang et al. [8] showed that a single injection of PD98059 decreases spinal nerve ligation-induced mechanical allodynia.

The goal of our studies was to precisely determine how preemptive and then once daily for 7 days of PD98059 administration influences the development of neuropathic pain. Additionally, we examined using Western blot how PD98059 administration influences the CCI-elevated ERK, p38 and JNK protein levels. Moreover, we examined the influence of PD98059 on the spinal protein level of NF-kappaB and selected cytokines important for nociception transmission (IL-1beta, IL-6, IL-18, IL-10, iNOS). Additionally, we examined the possible influence of intrathecal single and repeated PD98059 administration on the effectiveness of morphine and/or buprenorphine in a rat model of neuropathy.

Materials and Methods

Animals

The rats (male Wistar, 300–350 g) were housed in cages with sawdust under a light/dark cycle (12/12 h, lights on at 08:00 h). Food and water were available without restrictions. All experiments were conducted according to the recommendations of IASP [29] and the NIH Guide for the Care and Use of Laboratory Animals. Experimental protocols were approved by the II Local Bioethics Committee from the National Ethics Committee for Experiments on Animals, at the Institute of Pharmacology, Polish Academy of Sciences (Cracow, Poland).

Surgery for intrathecal implantation of catheters

Catheters for intrathecal (i.t.) injection were implanted according to Yaksh and Rudy [30] and our earlier publications [16, 19, 31]. The 7.8 cm long catheter (PE 10, outside diameter of 0.4 mm, Intramedic; Clay Adams, Parsippany, NJ) had been washed by 70% (v/v) ethanol and flushed with sterile water for injection before implantation. Head of rats under pentobarbital anaesthesia (60 mg/kg i.p.) was fixed on a stereotaxic table (David Kopf Instruments, Tujunga, CA), and the atlanto-occipital membrane was incised. The catheter was slowly introduced into the subarachnoid space until the end of the cannula reaches the rostral level of the spinal cord lumbar enlargement (L4–L5). The catheter was tightened after the injection of 10 mcl of water to flush the cannula. The first few days after catheter implantation the rats were monitored for physical impairments and rats exhibiting motor deficits were not included to the experiments. Experiment began a minimum of 1 week after the surgery. The injections through the i.t. catheter were made slowly (1–2 min) in a volume of 5 mcl, followed by a 10 mcl water for injection.

Sciatic nerve injury

Chronic constriction injury (CCI) was made in rats under sodium pentobarbital anesthesia (60 mg/kg; intraperitoneal, i.p.) by four tied ligatures (4/0 silk) on the exposed right sciatic nerve. The ligatures with 1-mm spacing were made on nerve distal to the sciatic notch until a brief twitch in the respective limb. The procedure has been made according to Bennett and Xie [32] and was previously used in our studies [19, 16, 31]. After this type of nerve injury, all rats developed long-lasting allodynia and hyperalgesia which are characteristics of neuropathic pain.

Behavioral study

von Frey test.

An automatic von Frey apparatus (Dynamic Plantar Aesthesiometer Cat. No. 37400, Ugo Basile, Italy) was used to measure the degree of tactile allodynia. The animals were habituated in plastic cages with wire net floors 5 min before the experiment. The strengths of the von Frey stimuli ranged up to 26 g. The filament touch the midplantar surface of the ipsilateral paw and measurements were taken automatically as we described previously [16, 17, 25, 31]. No significant difference in paw reactions were noticed between the contralateral hind paw of CCI-exposed rats and control (naive) rats.

Cold plate test.

The cold plate test (Cold/Hot Plate Analgesia Meter No. 05044, Columbus Instruments, USA) was used to measure the degree of thermal hyperalgesia as was previously described [16, 17, 25, 31]. The temperature of the cold plate was set at 5°C. The cut-off latency was 30 s. The time between putting the rat into the cold plate apparatus and the reaction (lifting the hind paw) was recorded. In the group of naive rats, the reaction of the first hind paw withdrawal was measured. In the group of CCI-exposed rats the injured paw was the first to react in all cases.

Tail-flick test.

The pain threshold to a thermal stimuli in naïve rats was assessed by tail-flick latency evoked by a noxious hot stimuli, as determined by a tail-flick analgesic meter device (Tail Flick Analgesia Meter, IITC Life Science Inc., USA). The tail-flick test consisted of a beam of light focused on the dorsal tail surface 1 cm from the tip of the tail. The reaction time of the animal is thus determined and automatically recorded and the cut-off time for the tail-flick reaction was set to 9 s [18].

Drug administration

PD98059 (2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one) (Sigma-Aldrich, USA) was dissolved in 75% DMSO. The PD98059 (2.5 mcg/5 mcl, i.t.) was single or repeated preemptively administered 16 h and 1 h before CCI and then once daily for 7 days (the administration was according to our previous paper [17], [25]). The Vehicle-treated CCI-exposed rats received 75% DMSO according to the same schedule. There was no significant difference in pain behavior between no-treated and V_(DMSO)-treated CCI-exposed rats. This method of PD98059 or vehicle administration was used throughout the study and is referred to in the text as “repeated administration”. At day 7^th after CCI 30 min after PD98059 administration tactile allodynia was measured using von Frey test and thermal hyperalgesia was conducted using cold plate test. Additionally, at day 7^th after CCI the vehicle-treated and PD98059-treated rats received a single i.t. vehicle, morphine (2.5 mcg/5 mcl) or buprenorphine (2.5 mcg/5 mcl) injection 30 min after PD98059, and then 30 min later the von Frey and/or cold plate tests were repeated. Since the dose of morphine 2.5 mcg/5 mcl in naïve rats produced maximal analgesic effect in tail-flick test. We have used lower dose of morphine for co-administration experiments, so that we would be able to observe the possible enhancement of opioid effectiveness. The vehicle-treated and PD98059-treated naïve rats (uninjured rats) received a single i.t. vehicle, morphine (0.5 mcg/5 mcl) or buprenorphine (2.5 mcg/5 mcl) injection 30 min after PD98059, and then 30 min later the tail flick test was performed (S1 Table and S1 Fig).

Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) analysis

Ipsilateral part of the dorsal part of the lumbar (L4–L6) spinal cord were collected immediately after decapitation (7 days after CCI and 4 hours after the last i.t. administration of PD98059). The tissue samples were placed in individual tubes containing the tissue storage reagent RNAlater (Qiagen Inc.) and were stored at -70°C for RNA isolation. Total RNA was extracted using the TRIzol reagent (Invitrogen). The RNA concentration was measured using a NanoDrop ND-1000 Spectrometer (NanoDrop Technologies). Reverse transcription was performed on 1 mcg of total RNA using Omniscript reverse transcriptase (Qiagen Inc.) at 37°C for 60 min. RT reactions were carried out in the presence of an RNAse inhibitor (rRNAsin, Promega) and an oligo (dT16) primer (Qiagen Inc.). cDNA was diluted 1:10 with H₂O, and for each reaction, ~ 50 ng of cDNA synthesized from the total RNA of an individual animal was used for the quantitative real-time PCR (qRT-PCR) assay. qRT-PCR was performed using Assay-On-Demand TaqMan probes according to the manufacturer's protocol (Applied Biosystems), and the reactions were run on an iCycler device (BioRad, Hercules). The TaqMan primers used in experiments were as follow: Rn01527838_g1 (Hprt, hypoxanthine guanine rat hypoxanthine guanine phosphoribosyl transferase); Rn00580432_m1 (IL-1beta, interleukin 1 beta); Rn00561420_m1 (IL-6, interleukin 6); Rn01422083_m1 (IL-18, interleukin 18); Rn00561646_m1 (iNOS, inducible nitric oxide synthase); Rn00563409_m1 (IL-10, interleukin 10). The amplification efficiency for each assay (between 1.7 and 2) was determined by running a standard dilution curve. The cycle threshold values were calculated automatically by the iCycler IQ 3.0 software using the default parameters. RNA abundance was calculated as 2^{-(threshold cycle)}. HPRT transcript levels do not significantly change in CCI-exposed rats, therefore, served as an adequate housekeeping gene (S2 Fig and S2 Table).

Western blot analysis

Ipsilateral L4–L6 spinal cords were collected (7 days after CCI and 6 hours after the last i.t. administration of PD98059) in RIPA (Radio-Immunoprecipitation Assay) buffer with protease and phosphatase inhibitor cocktails (Sigma-Aldrich) and cleared by centrifugation (14000×g for 30 min, 4°C). The protein concentration in the supernatant was determined using the BCA Protein Assay Kit (Sigma-Aldrich). Samples containing 14 mcg of protein were heated in 4x Laemmli Sample Buffer 4x (250 mM Tris-HCl, pH 6.8, 4% LDS, 40% (w/v) glycerol, 0.02% bromophenol blue, and 15% beta-mercaptoethanol (Bio-Rad) for 5 min at 95°C and resolved by SDS—PAGE on 4–20% polyacrylamide gels (Criterion TGX, Bio-Rad). Following gel electrophoresis, the proteins were transferred by electroblotting to Immun-Blot PVDF membranes (Bio-Rad). Then, the transfer membranes were blocked for 1 h at 25°C using 5% non-fat dry milk (Bio-Rad) in Tris-buffered saline with 0.1% Tween 20 (TBST). Afterwards, the blots were incubated with the following anti-rat primary antibodies diluted in a Signal Boost Immunoreaction Enhancer Kit (Calbiochem) for 24 h at 4°C: p-p38 (Santa Cruz) 1:500; p-ERK1/2 (Santa Cruz) 1:500; p-JNK (Santa Cruz) 1:2000; p-NF-kappaB (Santa Cruz) 1:500; IL-1beta (Abcam) 1:1000; IL-6 (Invitrogen) 1:1000; iNOS (Sigma-Aldrich) 1:2000; IL-18 (R&D Systems) 1:1000; and IL-10 (Invitrogen) 1:2000. After four 5-minute washes in TBST, blots were incubated with anti-rabbit, anti-mouse or anti-goat secondary antibodies conjugated to horseradish peroxidase (HRP) diluted at 1:5000 in a Signal Boost Immunoreaction Enhancer Kit for 1 h at room temperature. After another four 5-minute washes in TBST, immunocomplexes were detected using Clarity Western ECL Substrate (Bio-Rad) and visualized with a Fujifilm Luminescent Image Analyzer LAS4000 System. The blots were washed 2 times for 5 minutes each in TBS, stripped using Restore Western Blot Stripping Buffer (Thermo Scientific), washed an additional 2 times for 5 minutes each in TBS, blocked and reprobed with an antibody against p38 (Santa Cruz) 1:500; ERK1/2 (Santa Cruz) 1:500; JNK (Santa Cruz) 1:2000; NF-kappaB (Santa Cruz) 1:500 and/or GAPDH 1:5000 (Millipore) as an internal loading control diluted in a Signal Boost Immunoreaction Enhancer Kit. During our procedures the membranes were used for multiple antibodies analysis and also were cut at the level, which allow us to investigate factors with different molecular weight (molecular weight are applied by the companies, which purchase the antibodies—more details is in Supporting information’s: S3 Table.), therefore we are not able to present full-length of immunoblots (S3 Fig). The relative levels of immunoreactivity were quantified by densitometry using Fujifilm Multi Gauge software. The immunoblots shown are representative of 4–8 individual samples.

Data analysis

The behavioral data are presented as the mean ± S.E.M and the exact number of animals per group is placed on the description of the figures. The results of the experiments were evaluated using one-way analysis of variance (ANOVA). There was no significant difference between naïve and sham operated animals (e.g. 7 day in von Frey test values are as follows: naïve 25.5 g ± 0.3 and sham 25.1 g ± 0.5 and cold plate test values are as follows: naïve 28.0 s ± 0.8 and sham 28.5 s ± 0.9). The inter-group differences were analyzed with Bonferroni’s multiple comparison test. ***p<0.001 indicate significant differences compared to the control group (naïve rats); ^#p<0.05, ^##p<0.01 and ^###p<0.001 indicate significant differences compared to the vehicle-treated CCI-exposed or naïve rats; ^$ $p<0.01 and ^$ $ $p<0.001 indicate significant differences compared to the repeated or single PD-treated CCI-exposed rats which received single morphine or buprenorphine injection; °p<0.05 and °°°p<0.001 indicate significant differences between repeated or single PD-treated CCI-exposed or naive rats to repeated or single PD-treated CCI-exposed or naive rats which received single morphine or buprenorphine injection.

The biochemical data are presented as the fold change of control (naïve rats) from mean ± S.E.M. of the ipsilateral sides of the dorsal lumbar spinal cord and the exact number of samples per group is placed on the description of the figures. There was no significant difference between naïve and sham operated animals e.g. for IL-18, IL-6, IL-1beta and iNOS protein level values are as follows: 1 ± 0.2 vs 0.9 ± 0.2; 1 ± 0.1 vs. 1.1 ± 0.1; 1 ± 0.1 vs. 1.12 ± 0.1; 1 ± 0.11 vs. 1.0 ± 0.1, respectively. The results for phosphorylated form of p38, ERK1/2, JNK and NF-kappaB were normalized to their total protein level in the same sample and were then expressed as a ratio of the average optical density values obtained for naïve animals. The inter-group differences were analyzed using one-way ANOVA followed by Bonferroni’s multiple comparison test. *p<0.05, **p<0.01 and ***p<0.001 indicate significant differences compared to the control group (naïve rats); ^#p<0.05, ^##p<0.01 and ^###p<0.001 indicate significant differences compared to the vehicle-treated CCI-exposed rats.

All graphs were prepared using GraphPad Prism software (version 5.0).

Results

The effect of repeated i.t. administration of PD98059 on allodynia and hyperalgesia three and seven days after CCI in rats

The influence of repeated i.t. administration of PD98059 (2.5 mcg), delivered at 16 h and 1 h before ligation of the sciatic nerve and then once daily for seven days, on mechanical allodynia and thermal hyperalgesia was measured three and seven days following CCI using von Frey (Fig 1A) and cold plate (Fig 1B) tests, respectively. In CCI-exposed rats the allodynia was measured three (15.1 g ± 1.3, n = 7) and seven (14.21 g ± 0.44, n = 28) days following CCI in comparison to the control rats (25.5 g ± 0.3, n = 7 and 25.7 g ± 0.2, respectively, n = 17) (Fig 1A). Simultaneously, the hyperalgesia was observed three (11.5 s ± 1.8, n = 7) and seven (11.4 s ± 0.88, n = 28) days following CCI in comparison to the control rats (28.0 s ± 0.5, n = 7 and 28.0 s ± 0.8, n = 17, respectively) (Fig 1B).

[Figure omitted. See PDF.]

Fig 1. Effect of PD98059 on the development of neuropathic pain symptoms.

Effect of PD98059 (2.5 mcg/5 mcl; i.t.; 16 h and 1 h before CCI and then once daily for 7 days) on the development of mechanical allodynia (A; von Frey test) and thermal hyperalgesia (B; cold plate) on days 3 and 7 after CCI. Pain was assessed using von Frey and cold plate tests 30 min after the last drug administration, and the data are presented as the means ± SEM. The inter-group differences were analyzed with ANOVA and Bonferroni’s multiple comparison test. ***p<0.001 indicates a significant difference compared to the control group (C), and ^#p< 0.05 or ^###p<0.001 indicates a significant difference compared to the V-CCI rats (ANOVA, Bonferroni’s test). The number of animals per group—day 3: C n = 7; V-CCI n = 7; PD-CCI n = 10; day 7: C n = 17; V-CCI n = 28; PD-CCI n = 26. C, control,; V, vehicle, PD, PD98059. The a line is drawn at value that represents the cut-off.

https://doi.org/10.1371/journal.pone.0138583.g001

Repeated treatment with PD98059 attenuated mechanical allodynia measured by the von Frey test three (18.0 g ± 0.8, n = 10) and seven (20.21 g ± 0.67, n = 26) days after CCI in comparison to the vehicle-treated CCI-exposed rats (15.1 g ± 1.3, n = 7 and 14.21 g ± 0.44, n = 28, respectively) (Fig 1A). Furthermore, the repeated injections of PD98059 diminished thermal hyperalgesia, as was evaluated by the cold plate test, three (17.5 s ± 2.1, n = 10) and seven (25.54 s ± 1.03, n = 26) days following CCI compared to vehicle-treated CCI-exposed rats (11.5 s ± 1.8, n = 7 and 11.4 s ± 0.88, n = 28, respectively) (Fig 1B).

The effect of repeated i.t. administration of PD98059 on the protein level of MAPK members (p38, ERK1/2, JNK) and NF-kappaB in the spinal cord on day seven after injury in CCI-exposed rats

The protein levels of phosphorylated and non-phosphorylated p38, ERK1/2, JNK and NF-kappaB in the ipsilateral dorsal spinal cord (L4–L6) were examined seven days after CCI using Western blot technique. The p38 protein level (38kDa) was increased in vehicle-treated CCI-exposed rats and repeated PD98059 administration prevented its upregulation in neuropathic rats (Fig 2A). The increased level of ERK1/2 (44/42kDa) in CCI-exposed rats was not observed in group which received repeated administration PD98059 (Fig 2B). In case of JNK, the 46kDa isoform was upregulated in CCI-exposed rats (Fig 2C), however the changes of 54kDa JNK isoform was not detected (data not shown). Repeated administration of PD98059 resulted inhibition of upregulation of JNK 46kDa isoform in neuropathic rats (Fig 2C), and had no influence on JNK 54kDa isoform (data not shown). The NF-kappaB (65kDa) protein level was increased in CCI-exposed rats compared to control animals (Fig 2D) and repeated PD98059 administration prevented its upregulation in neuropathic animals (Fig 2D).

[Figure omitted. See PDF.]

Fig 2. Effect of PD98059 on the p38, ERK1/2, JNK and NF-kappaB protein level in neuropathic pain.

Effect of PD98059 (2.5 mcg/5 mcl; i.t.; 16 h and 1 h before CCI and then once daily for 7 days) on the protein levels of p38 (A), ERK1/2 (B), JNK (C) and NF-kappaB (D) in the ipsilateral dorsal part of the lumbar spinal cord on day 7 after CCI. PD98059 prevent the upregulation of the protein levels of p38, ERK1/2, JNK and NF-kappaB during neuropathic pain. The data are presented as the fold change of control. The number of individual samples per group Fig A-D: C n = 4–6; V-CCI n = 5–6; PD-CCI n = 5–7. The results for phosphorylated form of p38, ERK1/2, JNK and NF-kappaB were normalized to their total protein level in the same sample and were then expressed as a ratio of the average optical density values obtained for naïve animals. Inter-group differences were analyzed using Bonferroni's multiple comparison test. *p<0.05, **p<0.01 and ***p<0.001 indicates a significant difference compared to the control group (C), and ^#p<0.05 indicate significant differences compared to the V-CCI rats (ANOVA, Bonferroni’s test). C, control; V, vehicle; PD, PD98059.

https://doi.org/10.1371/journal.pone.0138583.g002

The effect of repeated i.t. administration of PD98059 on spinal pronociceptive factors (IL-1beta, IL-6, IL-18 and iNOS) and antinociceptive factor (IL-10) on day seven after injury in CCI-exposed rats

The mRNA levels of IL-1beta, IL-6, IL-18, iNOS and IL-10 in the ipsilateral dorsal spinal cord (L4–L6) were examined seven days after CCI using qRT-PCR assay. The level of IL-1beta, iNOS and IL-18 were upregulated in CCI-exposed rats compared to control animals (Fig 3A, 3B and 3D) but the repeated PD98059 administration prevent increased of iNOS (Fig 3B) level. We observed in vehicle-treated CCI-exposed rats that the IL-6 (21 kDa) protein level was highly increased but the IL-6 mRNA level shown only tendency to increase and the repeated administration of PD98059 had not significant effect on IL-6 mRNA (Fig 3C).

[Figure omitted. See PDF.]

Fig 3. Effect of PD98059 on the mRNA and protein level of pro-inflammatory factors (IL-1beta, iNOS, IL-6 and IL-18) and anti-inflammatory factor (IL-10) in neuropathic pain.

Effect of PD98059 (2.5 mcg/5 mcl; i.t.; 16 h and 1 h before CCI and then once daily for 7 days) on the mRNA and protein levels of IL-1beta (A, F), iNOS (B, G), IL-6 (C, H), IL-18 (D, I) and IL-10 (E, J) in the ipsilateral dorsal part of the lumbar spinal cord on day 7 after CCI. PD98059 prevent the upregulation of the mRNA levels of iNOS (B) and induced expression of mRNA for IL-10 (E), but did not influence the level of IL-1beta (A), IL-6 (C) and IL-18 (D) in the spinal cord during neuropathic pain. Repeated PD98059 treatment prevent the upregulation of the protein levels of IL-1beta (F), iNOS (G), IL-6 (H) and induced IL-10 (J), but did not influence the level of IL-18 (I) in the spinal cord during neuropathic pain. The data are presented as the fold change of control. The number of individual samples per group Figs A-E: C n = 4–5; V-CCI n = 6; PD-CCI n = 4–5; Figs F-J: C n = 4–6; V-CCI n = 5–8; PD-CCI n = 6–7. Inter-group differences were analyzed using Bonferroni's multiple comparison test. *p<0.05, **p<0.01 and ***p<0.001 indicate significant differences compared to the control group (C), and ^##p<0.01 and ^###p<0.001 indicate significant differences compared to the V-CCI rats (ANOVA, Bonferroni’s test). C, control; V, vehicle; PD, PD98059.

https://doi.org/10.1371/journal.pone.0138583.g003

Seven days following CCI the changes between mRNA levels of IL-10 in control and CCI-exposed rats were not observed (Fig 3E). However, the repeated administration of PD98059 for seven days after CCI induced strong upregulation of IL-10 mRNA level (Fig 3E).

The protein levels of IL-1beta, IL-6, IL-18, iNOS and IL-10 in the ipsilateral dorsal spinal cord (L4–L6) were examined seven days after CCI using Western blot technique. The level of IL-1beta (17 kDa) and iNOS (130 kDa) were similarly upregulated in CCI-exposed rats compared to control animals (Fig 3F and 3G) and the repeated PD98059 administration prevent increased of both IL-1beta (Fig 3F) and iNOS (Fig 3G) protein levels. We have showed that during neuropathic pain, PD98059 administration prevent upregulation of the spinal protein levels of IL-1beta, iNOS, IL-6, but not IL-18. Using qRT-PCR methods, we indicated that PD98059 administration prevent the upregulation of the spinal level of mRNA for iNOS, but not for IL-1beta, IL-6 and IL-18. In vehicle-treated CCI-exposed rats the upregulation of IL-18 (18 kDa) protein level was observed and the repeated treatment with PD98059 had not influenced on the level of this interleukin (Fig 3I).

Seven days following CCI the changes between levels of IL-10 (40 kDa) in control and CCI-exposed rats were not observed (Fig 3J). However, the repeated administration of PD98059 for seven days after CCI induced strong upregulation of IL-10 protein level (Fig 3J).

The effect of repeated i.t. administration of PD98059 on morphine analgesia on day seven after injury in CCI-exposed rats

In CCI-exposed rats repeated intrathecal PD98059 (2.5 mcg) administration produced after 30 min a strong anti-allodynic effect (20.5 g ± 1.0, n = 10) as measured on day seven compared to vehicle-treated animals (13.08 g ± 0.5, n = 10; Fig 4A). Single injection of morphine attenuated on allodynia (20.1 g ± 0.8, n = 10, Fig 4A). Repeated intrathecal PD98059 (2.5 mcg) administration improved the response to morphine (24.8 ± 0.7, n = 7, Fig 4A).

[Figure omitted. See PDF.]

Fig 4. Effect of PD98059 on opioid analgesia in a naive and neuropathic rats.

Effect of repeated vehicle or PD98059 administration (2.5 mcg/5 mcl; i.t.; 16 h and 1 h before CCI and then once daily for 7 days) on the analgesic effects of a single injection of morphine (5 mcg/5 mcl; i.t.) in CCI-exposed rats on day 7 after injury as measured by von Frey (A) and cold plate (B) in neuropathic animals. Effect of a single administration of vehicle or PD98059 (2.5 mcg/5 mcl) on a single i.t. injection of morphine (C, 2.5 mcg/5 mcl) and buprenorphine (D, 2.5 mcg/5 mcl) as measured by von Frey in neuropathic animals. Effect of a single administration of vehicle or PD98059 (2.5 mcg/5 mcl) on a single i.t. injection of morphine (E, 0.5 mcg/5 mcl) and buprenorphine (F, 2.5 mcg/5 mcl) as measured by tail flick test in naive animals. Behavioral tests were conducted 30 min after vehicle or PD98059 administration and then 30 min after a single vehicle, morphine or buprenorphine injection. Data are presented as the means ± SEM. The inter-group differences were analyzed using ANOVA and Bonferroni’s multiple comparison test. ^###p<0.001 indicates a significant difference compared to the control group; ^$ $p<0.01 and ^$ $ $p<0.001 indicate significant differences compared to the repeated or single PD-treated CCI-exposed rats which received single morphine or buprenorphine injection, and °p<0.05, and °°°p<0.001 indicate significant differences between repeated or single PD-treated CCI-exposed or naive rats to repeated or single PD-treated CCI-exposed or naive rats which received single morphine or buprenorphine C, control; V, vehicle; PD, PD98059. The number of animals per group—Figs A&B: V+V-CCI n = 10; PD+V-CCI n = 10, V+M-CCI n = 10, PD+M-CCI n = 7; Fig C: V+V-CCI n = 10; PD+V-CCI n = 10, V+M-CCI n = 8, PD+M-CCI n = 8; Fig D: V+V-CCI n = 10; PD+V-CCI n = 10, V+M-CCI n = 8, PD+M-CCI n = 7; Fig E: V+V-CCI n = 12; PD+V-CCI n = 10, V+M-CCI n = 7, PD+M-CCI n = 6; Fig F: V+V-CCI n = 8; PD+V-CCI n = 12, V+B-CCI n = 6, PD+B-CCI n = 6.

https://doi.org/10.1371/journal.pone.0138583.g004

Similarly, repeated intrathecal PD98059 (2.5 mcg) administration produced potent anti-hyperalgesic effect (25.9 s ± 1.4, n = 10) on day seven after CCI compared to (10.96 s ± 0.9, n = 10) vehicle-treated CCI rats (Fig 4B). Single injection of morphine attenuated on hyperalgesia (22.43 g ± 1.5, n = 10, Fig 4B) and repeated intrathecal PD98059 (2.5 mcg) administration enhanced morphine-induced analgesia (29.2 s± 0.8, n = 7, Fig 4B).

The effect of single i.t. administration of PD98059 on morphine and buprenorphine analgesia on day seven after injury in CCI-exposed rats

In CCI-exposed rats single intrathecal PD98059 (2.5 mcg) administration produced also significant antiallodynic effect after 30 min as assessed at day 7 by the von Frey test (18.5 g ± 0.55, n = 10; Fig 4C and 4D). Single injection of morphine attenuated the allodynia (19.6g ± 0.6, n = 8, Fig 4C). Single intrathecal PD98059 (2.5 mcg) administration enhanced morphine-induced analgesia (24.2 ± 0.63, n = 8, Fig 4C). Also single injection of buprenorphine produced analgesic effect as assessed by the cold plate test (18.8 ± 1.05, n = 8, Fig 4D). Single intrathecal PD98059 (2.5 mcg) administration enhanced buprenorphine-induced analgesia (23.25 ± 0.62, n = 7, Fig 4D).

The effect of single i.t. administration of PD98059 on morphine and buprenorphine analgesia in naive rats

In naïve rats a single intrathecal injection of PD98059 (2.5 mcg) produced no significant analgesic effect as assessed by the tail flick test (V-treated 3.8 s ± 0.17, n = 12 vs. PD98059-treated 4.6 s ± 0.32, n = 10; Fig 4E and 4F). Single intrathecal morphine (0.5 mcg) administration produced antinociceptive effect (5.8 s ± 0.66, n = 7, Fig 4E). Also single injection on buprenorphine (2.5 mcg) produced analgesic effect (7.6 s ± 0.7, n = 6, Fig 4F). However, a single intrathecal administration of PD98059 did not potentiated morphine (Fig 4E) and buprenorphine-induced (Fig 4F) analgesia as measured in tail-flick test 30 min after opioids i.t. administration.

Discussion

In the present paper we have demonstrated that PD98059 administration can diminish chronic constriction sciatic nerve injury-induced allodynia and hyperalgesia 3 and 7 days after CCI. Similar to our study, Zhuang et al., in 2005 [8] presented that a single injection of PD98059 into the lumbar CSF space inhibited spinal nerve ligation-induced (SNL)-induced mechanical allodynia. In 2014, van den Heuvel [33] et al. demonstrated that the intrathecal administration of PD98059 significantly reduced mechanical hyperalgesia in rats after plantar surgical incision. In mice, intraperitoneal administration of PD98059 (10 mg/kg) reduced inflammation in a carrageenan pain model [34]. Alessandrini et al. [35] observed that treatment of mice with PD98059 before focal cerebral ischemia provides protection against damage. Clemons et al. have shown that PD98059 can also significantly relieve cerulein-induced acute pancreatitis [36]. Our results show for the first time that PD98059 has not only analgesic effects, but also potentiates morphine and buprenorphine analgesia. Our Western blot studies have shown that PD98059, an inhibitor of MEK1/2, downregulated the CCI-elevated p-ERK1/2, as well as p-p38, p-JNK and p-NF-kappaB protein levels in the spinal cord in neuropathy. Moreover, PD98059 shifts the balance from a pro-inflammatory (IL-1beta, IL-6, and iNOS) to anti-inflammatory factors (IL-10).

Release of both pro- and anti-nociceptive cytokines by activated spinal immune and immune-like glial cells induce neuropathic pain which therefore is now considered as a neuro-immune disorder. Many of the changes occurring after tissue injury attempt to restore homeostasis in the damaged tissue, but lead to an altered balance that underlies ongoing chronic pain. Molecular components of the intracellular signaling cascades responsible for sensitization have been proposed as key targets for pharmacological treatments. Many signaling pathways can interact with each other through intracellular cross-talk. The results of our study suggest that MEKs (kinase enzymes that phosphorylate MAPKs) are useful targets because PD98059, an inhibitor of MEK1/2, can influence a variety of cell signaling pathways that are involved in neuropathic pain states (S4 Fig). Some inhibitors of ERK, p38, and JNK have been previously shown to reduce neuropathic pain symptoms in different animal models [13, 20, 25, 37, 38, 39, 40, 41].

In a neuropathic pain model the successive activation of ERK in spinal neurons, then in microglia, and finally in astrocytes was described [8, 42 4, 43 4]. Activation of ERK in spinal cord dorsal horn neurons is associated with the activation of nociceptive-specific sensory fibers and the promotion of intracellular events that contribute to central sensitization, which may be manifested at both behavioral and cellular levels [44]. Studies conducted by Xu et al. in 2006 [45] demonstrated enhanced activation of ERK1/2 and p38 after spinal cord injury in rats, which is consistent with our results. Furthermore, we indicate that repeated PD98059 administration prevents spinal upregulation of ERK1/2 and p38 during neuropathy, which suggests that PD98059 induce substantial changes in the intracellular pathways in cells. Zhuang et al. in 2005 [8] indicated that in SNL model the anti-allodynic effect of intrathecal PD98059 may be partially mediated by reducing ERK activation in DRG cells. All this studies suggested that ERK inhibitors may have a useful role in the management of neuropathy.

Some studies indicate that the active form of spinal JNK—pJNK increases after nerve injury [20, 37]. In a study by Zhuang et al. [20] the authors showed that only the p-JNK 46kDa isoform, but not p-JNK 54kDa isoform, is present in the spinal cord after injury, which corresponds well with our results. It has been previously shown that intrathecal infusion of JNK inhibitor, SP600125, attenuates neuropathic pain [1, 20]. We have shown for the first time that intrathecal delivery of PD98059 prevents upregulation of JNK 46kDa isoform level, so our results suggest that its influence on JNK can be one of the reason of pain relief.

Interestingly, in contrast to selective p38, ERK or JNK inhibitors, which often failed to reverse established pain states [1, 20, 41], PD98059 seems to be more effective. This specific MEK inhibitor appears inhibit a wide range of actions, and, most importantly, we found that it was also effective after a single injection when neuropathic pain was well established on day 7 after the injury.

It is well known that the p38 pathway phosphorylates and enhances the activity of many transcription factors, including NF-kappaB and the NF-kappaB regulates the transcription of various genes, including cytokines and iNOS [27, 42]. A number of studies indicate that NF-kappaB is involved in the pathogenesis of neuropathic pain. NF-kappaB activation occurs in the spinal cord after peripheral nerve injury, which is in agreement with our results and the findings of other authors [22, 23, 24]. In our previously published paper [25], chronic treatment with parthenolide (an inhibitor of NF-kappaB) showed that inhibition of the NF-kappaB pathway produced strong analgesic effects. Downregulation of NF-kappaB activation after parthenolide treatment was correlated with reduction of pronociceptive factor (IL-1beta, IL-18 and iNOS) at the spinal cord level of CCI-exposed rats [46]. The effect obtained by PD98059 treatment was similar in the case of allodynia, but stronger in the case of thermal hyperalgesia. Interestingly, using Western blot analysis, we showed that PD98059 administration prevents upregulation of NF-kappaB increased after CCI. Those findings suggests that NF-kappaB activation is one of the mechanisms of analgesia during neuropathic pain.

It is now known that the regulation of cytokine biosynthesis in many cell types is mediated through the activation of MAPK family members (JNK, p38, and ERK1/2). PD98059 diminished the three MAPK signal transduction pathways and the activity of NF-kappaB, and as consequence, modulated nerve injury-induced cytokine changes. Interleukins are potent modulators of pain cascades on the spinal cord level after nerve injury, inducing pain through direct neuronal excitability. Other effects of cytokines include changes in intracellular MAPK signaling cascades, resulting in recruitment of macrophage and activation of glia. It is well documented that p38 plays a role in neuropathic pain, and this effect is correlated with microglia activation [13, 14, 16]. Strategies that lead to a reduction in pain include the inhibition of pronociceptive factors. In our recent paper [46] we have demonstrated that upregulated after CCI pronociceptive factors (like IL-1beta, IL-18, iNOS) at the spinal cord level are microglial origin and are correlated with p38MAPK and ERK1/2, inter alia, activation. Zhou et al. [47] have shown that downregulation of IL-1beta, IL-6 and TNFalpha was correlated with reduction of activated p38MAPK level after montelukast-treatment in CCI-exposed rats. It has been shown, that PD98059 intracisternally administered after the subcutaneous injection of interleukin-1beta attenuated the formalin-induced pain behavior [46]. These results suggest that the IL-1beta-induced central sensitization of nociception is mediated by the spinal MAPK pathways, which are activated in neurons and glia under pain conditions. The nociceptive factors that undergo the strongest activation during neuropathy include iNOS, IL-1beta, IL-18 and IL-6 [16, 31, 48–54]. We showed that during neuropathic pain, PD98059 administration prevented the upregulation of the spinal protein levels of IL-1beta, iNOS, IL-6, but not IL-18 what constitutes the novelty of this research. Using qRT-PCR methods, we indicated that PD98059 administration prevented the upregulation of the spinal level of mRNA for iNOS, but not for IL-1beta, IL-6 and IL-18. Similar to our qRT-PCR findings, Xu et al. [47] show that PD98059 attenuated the spinal injury-induced expression of iNOS mRNA. However, no studies currently show how PD98059 influences interleukin changes under pathological states in vivo. In 2014, Zhu et al. [55] demonstrated that PD98059 slightly decreased IL-6 in LPS-stimulated murine BV2 microglial cells in vitro. Several studies have shown that PD98059 suppresses IL-1beta-induced phosphorylation of Erk1/2 in rat C6 gliomas; however, it does not decrease IL-6 [56, 57]. In 2013, Meng et al. [58] demonstrated that PD98059 diminishes the LPS-induced overexpression of NO in rat vascular smooth muscle cells in vitro. In 1998, Foey et al. [59] proved that PD98059 inhibited LPS-induced IL-1beta in monocyte cell culture, nevertheless, it performed no influence on LPS-induced IL-10 production. On the contrary to results mentioned, PD98059 inhibited IL-10 secretion by LPS-activated macrophages [60].

Our behavioral studies show that PD98059 prevented the upregulation of spinal protein level of IL-1beta that occurs following nerve injury and in contrast, induced the upregulation of IL-10. Studies conducted by Milligan et al. [61] and Ledeboer et al. [62] have shown that intrathecal administration of IL-10 suppresses neuropathic pain symptoms. The role of IL-10 in the nervous system is still not explained and many authors hypothesized that it may interact with microglia by preventing the release of IL-6 and IL-1beta [52, 63, 64]. IL-10 is an antinociceptive cytokine and PD98059 significantly increased the level of this cytokine. Therefore, in our opinion PD98059 restores the neuroimmune balance that is biased towards pronociceptive factors in the development of neuropathic pain.

The most important, new aspect of this study is that repeated and single administration of PD98059 potentiates the analgesic effect of single morphine and/or buprenorphine in CCI-exposed rats. Increasing evidence indicates that chronic morphine induces cytokine activation [12, 18, 65, 66] and that MAPKs are involved in agonist-induced phosphorylation of the opioid receptors [67]. In 2010, Wang et al. [68] showed that p-p38 was upregulated following chronic morphine treatment, other authors have shown that inhibition of p38 attenuated the development of morphine tolerance [12, 68]. We also demonstrated that minocycline antagonizes morphine antinociceptive tolerance during neuropathic pain [18]. In 2014, we hypothesized [25] that the modulation of NF-kappaB signaling during neuropathic pain may be one of the key factors associated with the loss of opioid effectiveness. In vitro studies have confirmed that NF-kappaB is involved in the transcriptional regulation of mor [69], dor [70] and kor [71] gene expression. It was shown previously that the ERK signaling cascade may be initiate by the Ca²⁺ entry into neurons via ionotropic glutamate receptors [72, 73]. In the paper of Ji et al. [7] the authors analyzed the involvement of ERK in producing pain hypersensitivity in formalin-induced pain model. In the mention work authors investigated that NMDA receptors contribute to ERK activation in the dorsal horn while MK-801, a blocker of the NMDA receptor channel, partially evoked ERK activation. Kawasaki et al. [39] suggested that the phosphorylation of the signaling molecule ERK could be a useful tool for studying neuronal sensitivity to opioid treatment under nerve injury conditions. We demonstrated in our earlier study [25] that high selective MEK1/2 inhibitor (U0126) significantly upregulated mRNA for classical opioid receptors, MOR, KOR and DOR at the spinal cord level 7 days after CCI. Those changes in opioid receptors expression may contribute to better analgesic effects of morphine and buprenorphine. Chronic morphine treatments induce the spinal activation of MEK1/2 and may be responsible for the altered properties of morphine [74]. In our experiments [25], we have shown that the chronic, intrathecal administration of selective inhibitor of MEK1/2 (U0126) improves the effectiveness of morphine in neuropathic pain, however those effect was weaker than in case of PD98059. The binding sites for PD98059 and U0126 on MEK1 appear to overlap but their mechanisms of action seem to be different [75, 76]. The differences between those two MEKs inhibitors also are manifested in specificity and potency [76, 77], which may explain better effects of PD98059.

Our results indicate that inhibition of the MAPK pathways by PD98059 has significant analgesic effects. The PD98059 robustly prevents the p38, ERK, JNK and NF-kappaB activation induced by nerve injury, and therefore, contributes to increasing the effectiveness of opioids such as morphine and buprenorphine in neuropathy. The data presented suggest that the blockade of the MAPKK pathways can be a potential target for a new and more successful therapeutic treatment for neuropathic pain.

Supporting Information

[Figure omitted. See PDF.]

S1 Fig. Drug administration.

https://doi.org/10.1371/journal.pone.0138583.s001

(DOCX)

S2 Fig. Amplification plot of HPTR transcripts.

https://doi.org/10.1371/journal.pone.0138583.s002

(DOCX)

S3 Fig. The full length of an exemplary immunoblot.

https://doi.org/10.1371/journal.pone.0138583.s003

(DOCX)

S4 Fig. The PD98059, an inhibitor of MEK1/2, induced changes during neuropathic pain.

https://doi.org/10.1371/journal.pone.0138583.s004

(DOCX)

S1 Table. Drug used in the study.

https://doi.org/10.1371/journal.pone.0138583.s005

(DOCX)

S2 Table. Primers used in the study.

https://doi.org/10.1371/journal.pone.0138583.s006

(DOCX)

S3 Table. Antibodies used in the study.

https://doi.org/10.1371/journal.pone.0138583.s007

(DOCX)

Acknowledgments

This work was supported by the National Science Centre, Poland, grant OPUS NCN 2011/03/B/NZ4/00042 grant and statutory funds. Katarzyna Popiolek-Barczyk and Magdalena Zychowska are Ph.D. students and have a scholarships from the KNOW, sponsored by the Ministry of Science and Higher Education, Republic of Poland. Manuscript was corrected by American Journal Experts.

Author Contributions

Conceived and designed the experiments: ER NK KPB AP MZ WM BP JM. Performed the experiments: ER NK KPB AP MZ WM BP JM. Analyzed the data: ER NK KPB AP MZ WM BP JM. Contributed reagents/materials/analysis tools: ER NK KPB AP MZ WM BP JM. Wrote the paper: ER NK KPB AP MZ WM BP JM.

Citation: Rojewska E, Popiolek-Barczyk K, Kolosowska N, Piotrowska A, Zychowska M, Makuch W, et al. (2015) PD98059 Influences Immune Factors and Enhances Opioid Analgesia in Model of Neuropathy. PLoS ONE 10(10): e0138583. https://doi.org/10.1371/journal.pone.0138583

References

1. Obata K, Yamanaka H, Kobayashi K, Dai Y, Mizushima T, Katsura H, et al. (2004) Role of mitogen-activated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation. J Neurosci 24: 10211–22. pmid:15537893

2. Zang Y, Xin WJ, Pang RP, Li YY, Liu XG (2011) Upregulation of Nav1.3 Channel Induced by rrTNF in Cultured Adult Rat DRG Neurons via p38 MAPK and JNK Pathways. Chin J Physiol 54: 241–6. pmid:22129822

3. Seger R, Krebs EG (1995) The MAPK signaling cascade. FASEB J 9: 726–35. pmid:7601337

4. Widmann C, Gibson S, Jarpe MB, Johnson GL (1999) Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79: 143–80. pmid:9922370

5. Ji RR, Gereau RW 4th, Malcangio M, Strichartz GR (2009) MAP kinase and pain. Brain Res Rev 60: 135–48. pmid:19150373

6. Lee MK, Han SR, Park MK, Kim MJ, Bae YC, Kim SK, et al. (2011) Behavioral evidence for the differential regulation of p-p38 MAPK and p-NF-kappaB in rats with trigeminal neuropathic pain. Mol Pain 7: 57. pmid:21816109

7. Ji RR, Baba H, Brenner GJ, Woolf CJ (1999) Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat Neurosci 2: 1114–9. pmid:10570489

8. Zhuang ZY, Gerner P, Woolf CJ, Ji RR (2005) ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 114: 149–59. pmid:15733640

9. Ji RR, Suter MR (2007) p38 MAPK, microglial signaling, and neuropathic pain. Mol Pain 3: 33. pmid:17974036

10. Sung CS, Wen ZH, Chang WK, Chan KH, Ho ST, Tsai SK, et al. (2005) Inhibition of p38 mitogen-activated protein kinase attenuates interleukin-1beta-induced thermal hyperalgesia and inducible nitric oxide synthase expression in the spinal cord. J Neurochem 94: 742–52. pmid:16033422

11. Chang YW, Waxman SG (2010) Minocycline attenuates mechanical allodynia and central sensitization following peripheral second-degree burn injury. J Pain 11: 1146–54. pmid:20418178

12. Cui Y, Liao XX, Liu W, Guo RX, Wu ZZ, Zhao CM, et al. (2008) A novel role of minocycline: attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. Brain Behav Immun 22: 114–23. pmid:17919885

13. Jin SX, Zhuang ZY, Woolf CJ, Ji RR (2003) p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 23: 4017–22. pmid:12764087

14. Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Koizumi S, Inoue K (2004) Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. GLIA 45: 89–95. pmid:14648549

15. Wen YR, Suter MR, Kawasaki Y, Huang J, Pertin M, Kohno T, et al. (2007) Nerve conduction blockade in the sciatic nerve prevents but does not reverse the activation of p38 mitogen-activated protein kinase in spinal microglia in the rat spared nerve injury model. Anesthesiology 107: 312–21. pmid:17667577

16. Rojewska E, Popiolek-Barczyk K, Jurga AM, Makuch W, Przewlocka B, Mika J (2014) Involvement of pro- and antinociceptive factors in minocycline analgesia in rat neuropathic pain model. J Neuroimmunol 277: 57–66. pmid:25304927

17. Mika J, Osikowicz M, Makuch W, Przewlocka B (2007) Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol 560: 142–9. pmid:17307159

18. Mika J, Wawrzczak-Bargiela A, Osikowicz M, Makuch W, Przewlocka B (2009) Attenuation of morphine tolerance by minocycline and pentoxifylline in naive and neuropathic mice. Brain Behav Immun 23: 75–84. pmid:18684397

19. Mika J, Popiolek-Barczyk K, Rojewska E, Makuch W, Starowicz K, Przewlocka B (2014) Delta-opioid receptor analgesia is independent of microglial activation in a rat model of neuropathic pain. PLoS One 9: e104420. pmid:25105291

20. Zhuang ZY, Wen YR, Zhang DR, Borsello T, Bonny C, Strichartz GR, et al. (2006) A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci 26: 3551–60. pmid:16571763

21. Gao YJ, Zhang L, Samad OA, Suter MR, Yasuhiko K, Xu ZZ, et al. (2009) JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci 29: 4096–108. pmid:19339605

22. Bethea JR, Castro M, Keane RW, Lee TT, Dietrich WD, Yezierski RP (1998) Traumatic spinal cord injury induces nuclear factor-kappaB activation. J Neurosci 18: 3251–3260. pmid:9547234

23. Ma W, Bisby MA (1998) Increased activation of nu clear factor kappa B in rat lumbar dorsal root ganglion neurons following partial sciatic nerve injuries. Brain Res 797: 243–54. pmid:9666140

24. Pollock G, Pennypacker KR, Mémet S, Israël A, Saporta S (2005) Activation of NF-kappaB in the mouse spinal cord following sciatic nerve transection. Exp Brain Res 165: 470–7. pmid:15912368

25. Popiolek-Barczyk K, Makuch W, Rojewska E, Pilat D, Mika J (2014) Inhibition of intracellular signaling pathways NF-kappaB and MEK1/2 attenuates neuropathic pain development and enhances morphine analgesia. Pharmacol Rep 66: 845–51. pmid:25149989

26. Zhang Q, Wang J, Duan MT, Han SP, Zeng XY, Wang JY (2013) NF-kappaB, ERK, p38 MAPK and JNK contribute to the initiation and/or maintenance of mechanical allodynia induced by tumor necrosis factor-alpha in the red nucleus. Brain Res Bull 99: 132–9. pmid:24161765

27. Karin M, Yamamoto Y, Wang QM (2004) The IKK NF-kappaB system: a treasure trove for drug development. Nat Rev Drug Discov 3: 17–26. pmid:14708018

28. Karim F, Wang CC, Gereau RW 4th (2001) Metabotropic glutamate receptor subtypes 1 and 5 are activators of extracellular signal-regulated kinase signaling required for inflammatory pain in mice. J Neurosci 21: 3771–9. pmid:11356865

29. Zimmermann M (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain16: 109–110. pmid:6877845

30. Yaksh TL, Rudy TA (1976) Chronic catheterization of the spinal subarachnoid space. Physiol Behav 17: 1031–1036. pmid:14677603

31. Rojewska E, Makuch W, Przewlocka B, Mika J (2014) Minocycline prevents dynorphin-induced neurotoxicity during neuropathic pain in rats. Neuropharmacology 86: 301–10. pmid:25172308

32. Bennett GJ, Xie YK (1988) A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33: 87–107. pmid:2837713

33. van den Heuvel I, Reichl S, Segelcke D, Zahn PK, Pogatzki-Zahn EM (2015) Selective prevention of mechanical hyperalgesia after incision by spinal ERK1/2 inhibition. Eur J Pain 19: 225–35. pmid:24976579

34. Di Paola R, Crisafulli C, Mazzon E, Genovese T, Paterniti I, Bramanti P, et al. (2009) Effect of PD98059, a selective MAPK3/MAPK1 inhibitor, on acute lung injury in mice. Int J Immunopathol Pharmacol 22: 937–50. pmid:20074457

35. Alessandrini A, Namura S, Moskowitz MA, Bonventre JV (1999) MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc Natl Acad Sci U S A 96: 12866–9. pmid:10536014

36. Clemons AP, Holstein DM, Galli A, Saunders C (2002) Cerulein-induced acute pancreatitis in the rat is significantly ameliorated by treatment with MEK1/2 inhibitors U0126 and PD98059. Pancreas 25: 251–9. pmid:12370536

37. Daulhac L, Mallet C, Courteix C, Etienne M, Duroux E, Privat AM, et al. (2006) Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate-dependent mechanisms. Mol Pharmacol 70: 1246–54. pmid:16868181

38. Ji RR, Befort K, Brenner GJ, Woolf CJ (2002) ERK MAP kinase activation insuperficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity. J Neurosci 22: 478–85. pmid:11784793

39. Kawasaki Y, Kohno T, Ji RR (2006) Different effects of opioid and cannabinoid receptor agonists on C-fiber-induced extracellular signal-regulated kinase activation in dorsal horn neurons in normal and spinal nerve-ligated rats. J Pharmacol Exp Ther 316: 601–7. pmid:16221738

40. Milligan ED, Twining C, Chacur M, Biedenkapp J, O'Connor K, Poole S, et al. (2003) Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci 23: 1026–40. pmid:12574433

41. Svensson CI, Marsala M, Westerlund A, Calcutt NA, Campana WM, Freshwater JD, et al. (2003) Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing. J Neurochem 86: 1534–44. pmid:12950462

42. Cheng XP, Wang BR, Liu H, You SW, Huang WJ, Jiao XY, et al. (2003) Phosphorylation of extracellular signal-regulated kinases 1/2 is predominantly enhanced in the microglia of the rat spinal cord following dorsal root transection. Neuroscience 119: 701–12. pmid:12809691

43. Ma W, Quirion R (2002) Partial sciatic nerve ligation induces increase in the phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) in astrocytes in the lumbar spinal dorsal horn and the gracile nucleus. Pain 99: 175–84. pmid:12237195

44. Woolf CJ, Salter MW (2000) Neuronal plasticity: increasing the gain in pain. Science 288: 1765–9. pmid:10846153

45. Xu Z, Wang BR, Wang X, Kuang F, Duan XL, Jiao XY, et al. (2006) ERK1/2 and p38 mitogen-activated protein kinase mediate iNOS-induced spinal neuron degeneration after acute traumatic spinal cord injury. Life Sci 79: 1895–905. pmid:16978658

46. Popiolek-Barczyk K, Kolosowska N, Piotrowska A, Makuch W, Rojewska E, Jurga A, et al. (2015) Parthenolide Relieves Pain and Promotes M2 Microglia/Macrophage Polarization in Rat Model of Neuropathy” Neural Plast.

47. Zhou C, Shi X, Huang H, Zhu Y, Wu Y (2014) Montelukast attenuates neuropathic pain through inhibiting p38 mitogen-activated protein kinase and nuclear factor-kappa B in a rat model of chronic constriction injury. Anesth Analg 118:1090–6. pmid:24686047

48. DeLeo JA, Colburn RW, Nichols M, Malhotra A (1996) Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res 16: 695–700. pmid:8887053

49. DeLeo JA, Tanga FY, Tawfik VL (2004) Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist 10: 40–52. pmid:14987447

50. Dominguez E, Rivat C, Pommier B, Mauborgne A, Pohl M (2008) JAK/STAT3 pathway is activated in spinal cord microglia after peripheral nerve injury and contributes to neuropathic pain development in rat. J Neurochem 107: 50–60. pmid:18636982

51. Lee HL, Lee KM, Son SJ, Hwang SH, Cho HJ (2004) Temporal expression of cytokines and their receptors mRNAs in a neuropathic pain model. Neuroreport 15: 2807–11. pmid:15597059

52. Mika J (2008) Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol Rep 60: 297–307. pmid:18622054

53. Miyoshi K, Obata K, Kondo T, Okamura H, Noguchi K (2008) Interleukin-18-mediated microglia/astrocyte interaction in the spinal cord enhances neuropathic pain processing after nerve injury. J Neurosci 28: 12775–87. pmid:19036970

54. Levy D, Kubes P, Zochodne DW (2001) Delayed peripheral nerve degeneration, regeneration, and pain in mice lacking inducible nitric oxide synthase. J Neuropathol Exp Neurol 60: 411–21. pmid:11379816

55. Zhu J, Jiang L, Liu Y, Qian W, Liu J, Zhou J, et al. (2015) MAPK and NF-κB Pathways Are Involved in Bisphenol A-Induced TNF-alpha and IL-6 Production in BV2 Microglial Cells. Inflammation 38: 637–48. pmid:25047101

56. Tanabe K, Nishimura K, Dohi S, Kozawa O (2009) Mechanisms of interleukin-1beta-induced GDNF release from rat glioma cells. Brain Res 1274: 11–20 pmid:19362079

57. Tanabe K, Kozawa O, Iida H (2011) Midazolam suppresses interleukin-1beta-inducedinterleukin-6 release from rat glial cells. J Neuroinflammation 8: 68. pmid:21682888

58. Meng Z, Yan C, Deng Q, Gao DF, Niu XL (2013) Curcumin inhibits LPS-induced inflammation in rat vascular smooth muscle cells in vitro via ROS-relative TLR4-MAPK/NF-kappaB pathways. Acta Pharmacol Sin 34: 901–11. pmid:23645013

59. Foey AD, Parry SL, Williams LM, Feldmann M, Foxwell BM, Brennan FM (1998) Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol 160: 920–8. pmid:9551930

60. Correa F, Mestre L, Docagne F, Guaza C (2005) Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol 145: 441–8. pmid:15821753

61. Milligan ED, Sloane EM, Langer SJ, Hughes TS, Jekich BM, Frank MG, et al. (2006) Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain. Pain 126: 294–308. pmid:16949747

62. Ledeboer A, Jekich BM, Sloane EM, Mahoney JH, Langer SJ, Milligan ED, et al. (2007) Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun 21: 686–98. pmid:17174526

63. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR (1993) Interleukin-10 Annu Rev Immunol 11: 165–90. pmid:8386517

64. Sawada M, Suzumura A, Hosoya H, Marunouchi T, Nagatsu T (1999) Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J Neurochem 72: 1466–71. pmid:10098850

65. Raghavendra V, Rutkowski MD, DeLeo JA (2002) The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci 22: 9980–9. pmid:12427855

66. Song P, Zhao ZQ (2001) The involvement of glial cells in the development of morphine tolerance. Neurosci Res 39: 281–6. pmid:11248367

67. Schmidt H, Schulz S, Klutzny M, Koch T, Händel M, Höllt V (2000) Involvement of mitogen-activated protein kinase in agonist-induced phosphorylation of the mu-opioid receptor in HEK 293 cells. J Neurochem 74: 414–22. pmid:10617147

68. Wang Z, Ma W, Chabot JG, Quirion R (2010) Morphological evidence for the involvement of microglial p38 activation in CGRP-associated development of morphine antinociceptive tolerance. Peptides 31: 2179–84. pmid:20804799

69. Kraus J, Börner C, Giannini E, Höllt V (2003) The role of nuclear factor kappaB in tumor necrosis factor-regulated transcription of the human mu-opioid receptor gene. Mol Pharmacol 64: 876–84. pmid:14500744

70. Chen YL, Law PY, Loh HH (2006) Sustained activation of phosphatidylinositol 3-kinase/Akt/nuclear factor kappaB signaling mediates G protein-coupled delta-opioid receptor gene expression. J Biol Chem 281: 3067–74. pmid:16316997

71. Law PY, Loh HH, Wei LN (2004) Insights into the receptor transcription and signaling: implications in opioid tolerance and dependence. Neuropharmacology 47(Suppl. 1): 300–11. pmid:15464146

72. Bading H, Greenberg ME (1991) Stimulation of protein tyrosine phosphorylation by NMDA receptor activation. Science 23;253:912–4. pmid:1715095

73. Fiore RS, Murphy TH, Sanghera JS, Pelech SL, Baraban JM (1993) Activation of p42 mitogen-activated protein kinase by glutamate receptor stimulation in rat primary cortical cultures. J Neurochem 61:1626–33. pmid:7693864

74. Komatsu T, Sakurada C, Sasaki M, Sanai K, Tsuzuki M, Bagetta G, et al. (2007) Extracellular signal-regulated kinase (ERK) and nitric oxide synthase mediate intrathecal morphine-induced nociceptive behavior. Neuropharmacology 52: 1237–43. pmid:17353023

75. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 92: 7686–9. pmid:7644477

76. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, et al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623–32. pmid:9660836

77. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270: 27489–94. pmid:7499206